Tyvyt
(sintilimab)Phase 3Monoclonal antibody
Innovent Biologics (Suzhou) Co. Ltd.Sintilimab is used to treat certain types of cancer, particularly non-small cell lung cancer and other solid tumors, by helping the immune system recognize and attack cancer cells.[1] Tyvyt is currently being investigated across 76 indications[3], with its most advanced program in Phase 3.[1]
Tyvyt is one of 1241 small molecule programs targeting Renal Cell Carcinoma. It is currently in Phase 3.
76
Indications
321
Total Trials
99
Active Trials
1,240
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 76 indications
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Adenocard
AstellasPreclinical
Zolymbus
AbbViePreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Duragesic
CCephalon
Preclinical
Acupan
YYonsei University
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Q4 2026
Phase 3Not yet recruiting
Hepatocellular Carcinoma
NCT06089369
Phase 2Recruiting
Metastatic Colorectal Cancer
NCT06685276
N/ARecruiting
Pancreatic Cancer
NCT06353646
Phase 2Recruiting
Clinical Trial
NCT06031285
Phase 1Recruiting
Non-Small Cell Lung Cancer
NCT05979818
Phase 2Not yet recruiting
Hepatocellular Carcinoma
NCT06512467
Clinical
Trials by Indication[1]
Hepatocellular Carcinoma22 trials
Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Unknown status·—·Phase 1·NCT05225116·20 enrolled
Show 19 more trials
Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma
Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06512467·30 enrolled
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT05617430·43 enrolled
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Not yet recruiting·IInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.·Phase 2/3·NCT07490262·680 enrolled
Non-Small Cell Lung Cancer14 trials
Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)
Not yet recruiting·—·Phase 2·NCT06198907·69 enrolled
Show 11 more trials
Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer
Not yet recruiting·—·Phase 2·NCT06221462·30 enrolled
Gastric Cancer14 trials
Show 11 more trials
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05627414·30 enrolled
A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
Recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT07263386·460 enrolled
Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
Enrolling by invitation·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06487715·42 enrolled
A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06564298·39 enrolled
Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04982939·210 enrolled
Sintilimab8 trials
SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC
Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·N/A·NCT07474103·49 enrolled
Show 5 more trials
Lymphoma6 trials
Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma
Unknown status·—·Phase 2·NCT04231370·20 enrolled
79 more indications
Esophageal Squamous Cell Carcinoma6 trials
Nasopharyngeal Carcinoma5 trials
Show 2 more trials
Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
Not yet recruiting·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT06680115·150 enrolled
Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
Recruiting·—··NCT05707819·43 enrolled
Neoadjuvant Therapy5 trials
Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT05429463·250 enrolled
Esophageal Cancer5 trials
Show 2 more trials
Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT03946969·30 enrolled
Pancreatic Cancer5 trials
Lung Cancer5 trials
Show 2 more trials
Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung Cancer
Unknown status·TThe First Affiliated Hospital of Xiamen University·Phase 1/2·NCT04840758·39 enrolled
Cervical Cancer4 trials
Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer
Not yet recruiting·—·Phase 2·NCT07088731·180 enrolled
Colorectal Cancer4 trials
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
Recruiting·—·Phase 2·NCT06543836·68 enrolled
Locally-advanced Rectal Cancer4 trials
Show 1 more trial
Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
Recruiting·—·Phase 2·NCT07040098·228 enrolled
Advanced NSCLC4 trials
Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT03874000·43 enrolled
Show 1 more trial
Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 1·NCT03987867·30 enrolled
Metastatic Colorectal Cancer3 trials
Metastasis3 trials
Efficacy and Safety3 trials
Advanced Solid Tumors3 trials
Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT05527821·36 enrolled
Chemotherapy3 trials
Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.
Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2·NCT04882462·100 enrolled
Adenocarcinoma3 trials
Renal Cell Carcinoma2 trials
Soft Tissue Sarcoma2 trials
Neoadjuvant Chemotherapy2 trials
First-line Treatment2 trials
Neoadjuvant Treatment2 trials
Neuroblastoma2 trials
Anti-PD-1 Antibody2 trials
Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma
Unknown status·—·Phase 2·NCT05461235·1 enrolled
Central Nervous System Lymphoma2 trials
Orelabrutinib, Sintilimab and Temozolomide in Relapsed or Refractory Central Nervous System Lymphoma
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04961515·19 enrolled
Premalignant Lesion1 trial
Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization
Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT04065737·29 enrolled
Gastroesophageal Junction Adenocarcinoma1 trial
Advanced or Metastatic Solid Tumour1 trial
Meningioma1 trial
Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent Meningioma
Unknown status·—·N/A·NCT04728568·15 enrolled
Patients With Advanced Solid Tumors1 trial
Stereotactic Body Radiotherapy1 trial
Liver Transplant1 trial
Colorectal Carcinoma1 trial
Combination Therapy1 trial
Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients
Recruiting·—·N/A·NCT06457477·50 enrolled
Undifferentiated Pleomorphic Sarcoma1 trial
Phase II Clinical Study1 trial
Radiotherapy1 trial
Safety and Efficacy1 trial
Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis
Unknown status·—·Phase 1·NCT04104074·20 enrolled
Cutaneous T-cell lymphoma1 trial
First Line Therapy1 trial
Gastric Adenocarcinoma1 trial
A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05594381·90 enrolled
Cholangiocarcinoma1 trial
Glioblastoma1 trial
Clinical Trial1 trial
Head and Neck Tumors1 trial
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06240689·104 enrolled
PD-1antibody1 trial
The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients
Active, not recruiting·—·N/A·NCT06357806·45 enrolled
Liver Cancer1 trial
Ovarian Cancer1 trial
A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer
Completed·—·Phase 2·NCT03989336·84 enrolled
Pancreatic Carcinoma1 trial
Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy
Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05627427·60 enrolled
Growth1 trial
Esophageal Adenocarcinoma1 trial
Rectal Cancer1 trial
EBV-Positive DLBCL, Nos1 trial
Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04181489·55 enrolled
Advanced1 trial
Ovarian Clear Cell Carcinoma1 trial
Adjuvant Therapy1 trial
Unresectable1 trial
Liver Resection1 trial
Colon Adenocarcinoma1 trial
Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma
Recruiting·—·Phase 2·NCT07468630·106 enrolled
Drug Resistance1 trial
Endometrial Cancer1 trial
Induction Chemotherapy1 trial
Biliary Tract Cancer1 trial
T Cell1 trial
Breast Cancer1 trial
Treatment1 trial
Thyroid Cancer1 trial
Intrahepatic Cholangiocarcinoma1 trial
Hypofractionated Radiotherapy1 trial
Head and Neck Squamous Cell Carcinoma1 trial
Prospective1 trial
Rare Tumor1 trial
PLATFORM Study of Precision Medicine for Rare Tumors
Recruiting·—·Phase 2·NCT04423185·770 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for sintilimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details